Aurinia Pharmaceuticals (AUPH) Total Non-Current Liabilities (2019 - 2026)

Aurinia Pharmaceuticals (AUPH) has 6 years of Total Non-Current Liabilities data on file, last reported at $162.1 million in Q4 2024.

• Quarterly Total Non-Current Liabilities rose 1.79% year-over-year to $162.1 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $162.1 million (up 1.79% YoY) and the FY2024 annual result came in at $162.1 million, up 1.79% from the prior year.
• Total Non-Current Liabilities grew to $162.1 million in Q4 2024, from $150.5 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $162.1 million in Q4 2024 to a low of $29.0 million in Q1 2021.
• A 5-year average of $88.2 million and a median of $49.1 million in 2023 frame the typical range for Total Non-Current Liabilities.
• Annual changes were most pronounced in 2023 — Total Non-Current Liabilities jumped 251.47% — and 2024, when it fell 1.52%.
• Tracing AUPH's Total Non-Current Liabilities over 5 years: stood at $39.6 million in 2020, then rose by 21.86% to $48.3 million in 2021, then gained by 10.25% to $53.2 million in 2022, then jumped by 199.12% to $159.2 million in 2023, then gained by 1.79% to $162.1 million in 2024.
• The last three Total Non-Current Liabilities figures came in at $162.1 million (Q4 2024), $150.5 million (Q3 2024), and $148.0 million (Q2 2024), per Business Quant data.